NAMSA Acquires Labcorp Device Testing Assets to Expand MedTech
Toledo, Ohio — January 8, 2026 — NAMSA, a global leader in medical device testing, clinical research, and regulatory...
AI in Healthcare Alzheimer’s Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology cancer therapy Cell Therapy cGxP Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy GMP GMP compliance Immuno-Oncology immunology Immunotherapy Medical Devices MedTech medtech innovation Monoclonal Antibody Oncology oncology innovation Orphan Drug orphan drug designation patient access Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory approval regulatory compliance targeted therapy
Toledo, Ohio — January 8, 2026 — NAMSA, a global leader in medical device testing, clinical research, and regulatory...
PARIS – October 24, 2025 Sanofi reported a 7.0% sales increase at constant exchange rates (CER) for Q3 2025,...
BURLINGTON, N.C. – October 23, 2025 Labcorp (NYSE: LH), a global leader in laboratory diagnostics, announced it will soon...
